99mTc-anti-TNF-{alpha} antibody for the imaging of disease activity in pulmonary sarcoidosis
In this study we evaluated scintigraphy with technetium-99m (99mTc)-labelled infliximab for the imaging of disease activity in patients with pulmonary sarcoidosis.
10 patients were studied using single photon emission computed tomography/computed tomography (CT) 6 h and 20 h after intravenous administration of 370 MBq of 99mTc-infliximab. Correlation analysis was performed between tissue accumulation of 99mTc-infliximab and laboratory parameters (including soluble interleukin-2 receptor and angiotensin-converting enzyme), lung function parameters (including forced expiratory volume in 1 s and the diffusing capacity of the lung for carbon monoxide) and 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT.
Analysis showed selective and variable accumulation of 99mTc-infliximab in the target tissue. Accumulation correlated positively with all four laboratory parameters and negatively with all four lung function parameters, yielding better correlations than serum TNF-α levels or 18F-FDG PET/CT.
99mTc-infliximab accumulation reflects the in situ TNF-α expression in an individual patient and therefore provides valuable information on the presence of the biological target for anti-TNF-α therapy.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Vis, R., Malviya, G., Signore, A., Grutters, J. C., Meek, B., van de Garde, E. M. W., Keijsers, R. G. M. Tags: Interstitial and orphan lung disease Original Articles: Sarcoidosis Source Type: research
More News: Carbon Monoxide Poisoning | CT Scan | Laboratory Medicine | PET Scan | Remicade | Respiratory Medicine | Sarcoidosis | SPECT | Study